ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.04B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.45M
Average 1.66M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$109.84M
FY 2025 · Annual
-30.4% YoYInvesting Cash Flow
-$302.56M
FY 2025 · Annual
Financing Cash Flow
$49.88M
FY 2025 · Annual
+628.8% YoYCash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (249.88M) |
| Stock-Based Compensation | 63.62M | 68.2M | 66.42M | 67.05M | 0 |
| Change in Working Capital | (24.82M) | 37.99M | 18.13M | 4.16M | (89.76M) |
| Accounts Receivables | (16.12M) | 2.26M | (39.27M) | (2.35M) | (43.54M) |
| Inventory | (4.21M) | 2.42M | (28.81M) | (49.55M) | (18.2M) |
| Accounts Payables | (1.62M) | 5.87M | 4.8M | (1.35M) | (5.29M) |
| Other Working Capital | (2.88M) | 27.44M | 81.41M | 57.4M | (22.73M) |
| Other Non-Cash Items | 75K | (6.28M) | (12.12M) | (155.82M) | 46.71M |
| Operating Cash Flow | (125.66M) | (114.04M) | 16.7M | 157.72M | 109.84M |
| Capital Expenditures | (1.12M) | 0 | (40.05M) | (523K) | (4.69M) |
| Acquisitions (Net) | 69.98M | 0 | (32.05M) | 0 | 0 |
| Purchases of Investments | (492.8M) | (363.17M) | (369.99M) | (505.1M) | (692.57M) |
| Sales of Investments | 422.82M | 436.42M | 442.03M | 328.57M | 493.53M |
| Other Investing Activities | (69.98M) | 0 | 32.05M | 146.52M | 0 |
| Investing Cash Flow | (71.1M) | 73.24M | 32M | (30.54M) | (302.56M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Effect of Forex Changes | 7K | 6K | (18K) | (94K) | 951K |
| Net Change in Cash | (178.59M) | (32.59M) | 73.81M | 133.93M | (141.89M) |
| Free Cash Flow | (126.78M) | (114.04M) | (23.35M) | 157.2M | 105.15M |
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is $105.1M. FCF conversion is 26.9% of net income. Operating cash flow was $109.8M, with capex of -$4.7M. The largest bridge item is Deferred Tax at -$249.9M.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Market cap
$9.17B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Market cap
$7.45B
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Market cap
$1.39B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Market cap
$1.25B
Alto Neuroscience, Inc.
NYSE:ANRO
Market cap
$1.18B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Market cap
$348.58M
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Market cap
$308.98M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Market cap
$241.27M
Anavex Life Sciences Corp.
NASDAQ:AVXL
Market cap
$86.53M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Market cap
$80.59M
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 8-K | Current report | Oct 23, 2026 |
Does ACAD generate free cash flow?
ACADIA Pharmaceuticals Inc. (ACAD) generated $105.15M of free cash flow in fiscal 2025.
How much operating cash flow does ACAD produce?
Operating cash flow was $109.84M, before capital expenditures of $4.69M.
Continue the stock analysis
Jump to another research area for this company.